<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27296985</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2016</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Antiviral activity of micafungin against enterovirus 71.</ArticleTitle><Pagination><StartPage>99</StartPage><MedlinePgn>99</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">99</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-016-0557-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71) is a major causative agent of hand-foot-mouth disease (HFMD) and also causes severe neurological complications, leading to fatality in young children. However, no effective therapy is currently available for the treatment of this infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We identified small-molecule inhibitors of EV71 from a screen of 968 Food and Drug Administration (FDA)-approved drugs, with which clinical application for EV71-associated diseases would be more feasible, using EV71 subgenomic replicon system. Primary hits were extensively evaluated for their antiviral activities in EV71-infected cells.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified micafungin, an echinocandin antifungal drug, as a novel inhibitor of EV71. Micafungin potently inhibits the proliferation of EV71 as well as the replication of EV71 replicon in cells with a low micromolar IC50 (~5 &#x3bc;M). The strong antiviral effect of micafungin on EV71 replicon and the result from time-of-addition experiment demonstrated a targeting of micafungin on virion-independent intracellular process(es) during EV71 infection. Moreover, an extensive analysis excluded the involvement of 2C and 3A proteins, IRES-dependent translation, and also that of polyprotein processing in the antiviral effect of micafungin.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our research revealed a new indication of micafungin as an effective inhibitor of EV71, which is the first case reporting antiviral activity of micafungin, an antifungal drug.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chonsaeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hyunju</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Anticancer Agent Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28116, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, 1 Chungdae-ro Seowon-gu, Cheongju-si, Chungcheongbuk-do, 28644, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong-Eun</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Anticancer Agent Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28116, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, 1 Chungdae-ro Seowon-gu, Cheongju-si, Chungcheongbuk-do, 28644, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jae-Hyoung</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology and Immunology, College of Pharmacy, Kangwon National University, 1 Gangwondaehak-gil, Chuncheon-si, Gangwon-do, 24341, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Miri</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anticancer Agent Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28116, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Mingu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anticancer Agent Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28116, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyungjin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hae Soo</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Jin Soo</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyejeong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Anticancer Agent Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28116, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Sunhee</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anticancer Agent Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28116, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Sang-Bae</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, 1 Chungdae-ro Seowon-gu, Cheongju-si, Chungcheongbuk-do, 28644, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jong Heon</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Cancer Cell and Molecular Biology Branch, Research Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Hyun-Jeong</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology and Immunology, College of Pharmacy, Kangwon National University, 1 Gangwondaehak-gil, Chuncheon-si, Gangwon-do, 24341, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chong-Kyo</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Meehyein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Virus Research and Testing Center, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon, 34114, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sungchan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anticancer Agent Research Center, Korea Research Institute of Bioscience &amp; Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28116, South Korea. sungchan@kribb.re.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomolecular Science, Korea University of Science and Technology, 217 Gajeong-ro, Daejeon, 34113, South Korea. sungchan@kribb.re.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054714">Echinocandins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055666">Lipopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>R10H71BSWG</RegistryNumber><NameOfSubstance UI="D000077551">Micafungin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054714" MajorTopicYN="N">Echinocandins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055666" MajorTopicYN="N">Lipopeptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077551" MajorTopicYN="N">Micafungin</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral drug</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Enterovirus 71 (EV71)</Keyword><Keyword MajorTopicYN="N">FDA-approved drug</Keyword><Keyword MajorTopicYN="N">Micafungin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27296985</ArticleId><ArticleId IdType="pmc">PMC4907259</ArticleId><ArticleId IdType="doi">10.1186/s12985-016-0557-8</ArticleId><ArticleId IdType="pii">10.1186/s12985-016-0557-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S, et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979;60:329&#x2013;340. doi: 10.1007/BF01317504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01317504</ArticleId><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J, Yeo SG, Hong EH, Lee BR, Kim JW, Kim J, Jeong H, Kwon Y, Kim H, Lee S, et al. Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a. Biomol Ther (Seoul) 2014;22:41&#x2013;46. doi: 10.4062/biomolther.2013.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2013.108</ArticleId><ArticleId IdType="pmc">PMC3936428</ArticleId><ArticleId IdType="pubmed">24596620</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, Yu CK, Su IJ, Liu CC. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003;188:564&#x2013;570. doi: 10.1086/376998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/376998</ArticleId><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol. 1999;73:1941&#x2013;1948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104435</ArticleId><ArticleId IdType="pubmed">9971773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Ng MM, Chu JJ. Developments towards antiviral therapies against enterovirus 71. Drug Discov Today. 2010;15:1041&#x2013;1051. doi: 10.1016/j.drudis.2010.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="pubmed">20974282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H, Kim C, Kim DE, Song JH, Choi M, Choi K, Kang M, Lee K, Kim HS, Shin JS, et al. Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antiviral Res. 2015;124:1&#x2013;10. doi: 10.1016/j.antiviral.2015.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.10.011</ArticleId><ArticleId IdType="pubmed">26526589</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Xu M, Yin Z. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res. 2013;97:183&#x2013;194. doi: 10.1016/j.antiviral.2012.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.12.005</ArticleId><ArticleId IdType="pubmed">23261847</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157:669&#x2013;679. doi: 10.1007/s00705-011-1222-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1222-6</ArticleId><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J, Wang Y, Sun Y, Huang J, Yan W, Wang J, Su D, Ni C, Li J, Rao Z, et al. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog. 2014;10:e1004422. doi: 10.1371/journal.ppat.1004422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, Lee YC, et al. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother. 2004;48:3523&#x2013;3529. doi: 10.1128/AAC.48.9.3523-3529.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.48.9.3523-3529.2004</ArticleId><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L, Wang X, Spyrou JA, Kelly J, Ren J, Grimes J, Puerstinger G, Stonehouse N, Walter TS, Hu Z, et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol. 2014;21:282&#x2013;288. doi: 10.1038/nsmb.2769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2769</ArticleId><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Falah N, Montserret R, Lelogeais V, Schuffenecker I, Lina B, Cortay JC, Violot S. Blocking human enterovirus 71 replication by targeting viral 2A protease. J Antimicrob Chemother. 2012;67:2865&#x2013;2869. doi: 10.1093/jac/dks304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks304</ArticleId><ArticleId IdType="pubmed">22865380</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995;69:4189&#x2013;4197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem. 1999;42:1213&#x2013;1224. doi: 10.1021/jm9805384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm9805384</ArticleId><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Chang HY, Lin PF, Chern JH, Hsu JT, Chang CY, Shih SR. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009;53:2740&#x2013;2747. doi: 10.1128/AAC.00101-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00101-09</ArticleId><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbinati C, Chiodelli P, Rusnati M. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules. 2008;13:2758&#x2013;2785. doi: 10.3390/molecules13112758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules13112758</ArticleId><ArticleId IdType="pmc">PMC6245429</ArticleId><ArticleId IdType="pubmed">19002078</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi HJ, Lim CH, Song JH, Baek SH, Kwon DH. Antiviral activity of raoulic acid from Raoulia australis against Picornaviruses. Phytomedicine. 2009;16:35&#x2013;39. doi: 10.1016/j.phymed.2008.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2008.10.012</ArticleId><ArticleId IdType="pubmed">19097770</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Yang Y, Xu Y, Ma C, Qin C, Zhang L. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J. 2011;8:483. doi: 10.1186/1743-422X-8-483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-483</ArticleId><ArticleId IdType="pmc">PMC3212826</ArticleId><ArticleId IdType="pubmed">22029605</ArticleId></ArticleIdList></Reference><Reference><Citation>Song JH, Choi HJ, Song HH, Hong EH, Lee BR, Oh SR, Choi K, Yeo SG, Lee YP, Cho S, Ko HJ. Antiviral activity of ginsenosides against coxsackievirus B3, enterovirus 71, and human rhinovirus 3. J Ginseng Res. 2014;38:173&#x2013;179. doi: 10.1016/j.jgr.2014.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgr.2014.04.003</ArticleId><ArticleId IdType="pmc">PMC4213867</ArticleId><ArticleId IdType="pubmed">25378991</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuzzati N. Analysis methods of ginsenosides. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;812:119&#x2013;133. doi: 10.1016/S1570-0232(04)00645-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1570-0232(04)00645-2</ArticleId><ArticleId IdType="pubmed">15556492</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794&#x2013;797. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kuppeveld FJ, Galama JM, Zoll J, Melchers WJ. Genetic analysis of a hydrophobic domain of coxsackie B3 virus protein 2B: a moderate degree of hydrophobicity is required for a cis-acting function in viral RNA synthesis. J Virol. 1995;69:7782&#x2013;7790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189721</ArticleId><ArticleId IdType="pubmed">7494289</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ooij MJ, Vogt DA, Paul A, Castro C, Kuijpers J, van Kuppeveld FJ, Cameron CE, Wimmer E, Andino R, Melchers WJ. Structural and functional characterization of the coxsackievirus B3 CRE(2C): role of CRE(2C) in negative- and positive-strand RNA synthesis. J Gen Virol. 2006;87:103&#x2013;113. doi: 10.1099/vir.0.81297-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81297-0</ArticleId><ArticleId IdType="pubmed">16361422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels E, Notebaart RA, Duijsings D, Lanke K, Vergeer B, Melchers WJ, van Kuppeveld FJ. Structure-function analysis of the coxsackievirus protein 3A: identification of residues important for dimerization, viral rna replication, and transport inhibition. J Biol Chem. 2006;281:28232&#x2013;28243. doi: 10.1074/jbc.M601122200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M601122200</ArticleId><ArticleId IdType="pubmed">16867984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R, van der Linden L, Thibaut HJ, Lanke KH, Leyssen P, Coutard B, De Palma AM, Canard B, Neyts J, van Kuppeveld FJ. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother. 2013;57:1952&#x2013;1956. doi: 10.1128/AAC.02084-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02084-12</ArticleId><ArticleId IdType="pmc">PMC3623316</ArticleId><ArticleId IdType="pubmed">23335743</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Choi K, Kang H, Lee SY, Chi SW, Lee MS, Song J, Im D, Choi Y, Cho S. Identification of a novel function of CX-4945 as a splicing regulator. PLoS One. 2014;9 doi: 10.1371/journal.pone.0094978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094978</ArticleId><ArticleId IdType="pmc">PMC3990583</ArticleId><ArticleId IdType="pubmed">24743259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H, Song J, Choi K, Kim H, Choi M, Lee SY, Kim C, Lee SJ, Song MJ, Kang H, et al. Efficient lytic induction of Kaposi's sarcoma-associated herpesvirus (KSHV) by the anthracyclines. Oncotarget. 2014;5:8515&#x2013;8527. doi: 10.18632/oncotarget.2335.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.2335</ArticleId><ArticleId IdType="pmc">PMC4226701</ArticleId><ArticleId IdType="pubmed">25237786</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer MH. Enterovirus infections: diagnosis and treatment. Semin Pediatr Infect Dis. 2002;13:40&#x2013;47. doi: 10.1053/spid.2002.29756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/spid.2002.29756</ArticleId><ArticleId IdType="pubmed">12118843</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitton JL, Cornell CT, Feuer R. Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol. 2005;3:765&#x2013;776. doi: 10.1038/nrmicro1284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1284</ArticleId><ArticleId IdType="pubmed">16205710</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Heggermont W, Lanke K, Coutard B, Bergmann M, Monforte AM, Canard B, De Clercq E, Chimirri A, Purstinger G, et al. The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C. J Virol. 2008;82:4720&#x2013;4730. doi: 10.1128/JVI.01338-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01338-07</ArticleId><ArticleId IdType="pmc">PMC2346740</ArticleId><ArticleId IdType="pubmed">18337578</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71:391&#x2013;396. doi: 10.1016/j.antiviral.2006.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2006.03.011</ArticleId><ArticleId IdType="pmc">PMC7132408</ArticleId><ArticleId IdType="pubmed">16675037</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto T, Fujie A, Sakamoto K, Tsurumi Y, Shigematsu N, Yamashita M, Hashimoto S, Okuhara M, Kohsaka M. WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo) 1994;47:1084&#x2013;1091. doi: 10.7164/antibiotics.47.1084.</Citation><ArticleIdList><ArticleId IdType="doi">10.7164/antibiotics.47.1084</ArticleId><ArticleId IdType="pubmed">7961156</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol. 2001;39(Suppl 1):55&#x2013;66. doi: 10.1080/mmy.39.1.55.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/mmy.39.1.55.66</ArticleId><ArticleId IdType="pubmed">11800269</ArticleId></ArticleIdList></Reference><Reference><Citation>Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362:1142&#x2013;1151. doi: 10.1016/S0140-6736(03)14472-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)14472-8</ArticleId><ArticleId IdType="pubmed">14550704</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyfeler R, Keller-Schierlein W. Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components. Helv Chim Acta. 1974;57:2459&#x2013;2477. doi: 10.1002/hlca.19740570818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hlca.19740570818</ArticleId><ArticleId IdType="pubmed">4613708</ArticleId></ArticleIdList></Reference><Reference><Citation>Masurekar PS, Fountoulakis JM, Hallada TC, Sosa MS, Kaplan L. Pneumocandins from Zalerion arboricola. II. Modification of product spectrum by mutation and medium manipulation. J Antibiot (Tokyo) 1992;45:1867&#x2013;1874. doi: 10.7164/antibiotics.45.1867.</Citation><ArticleIdList><ArticleId IdType="doi">10.7164/antibiotics.45.1867</ArticleId><ArticleId IdType="pubmed">1490877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>